The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Jackson-Perry D, Amstutz A(2025) Should we be paying more attention to HIV and adult ADHD? Lancet HIV(in press) DOI 10.1016/S2352-3018(25)00235-8, PubMed 40850324
Sachs-Strømmen K, Thorsteinsdottir H, Sakhi AK, Thomsen C, Lie A, Bjerre A, Lyche JL(2025) Urinary levels and estimated daily intake of phthalates and phenols in kidney transplanted Norwegian children Sci Total Environ, 998, 180251(in press) DOI 10.1016/j.scitotenv.2025.180251, PubMed 40845701
Michelsen TM, Sajjad MU, Haugen G, Moore L, Julian CG, Sørbye IK, Henriksen T(2025) Maternal body mass index is related to fetal uptake of glucose and oxygen via fetal insulin resistance rather than fetal glucose levels Philos Trans R Soc Lond B Biol Sci, 380(1933), 20240178 DOI 10.1098/rstb.2024.0178, PubMed 40836801